The aetiology of psoriasis: clues provided by benoxaprofen.
Twenty-four patients with psoriasis completed a double-blind trial of benoxaprofen for their cutaneous lesions. Six out of thirteen on the active drug showed very marked improvement. It is believed that benoxaprofen acts by interfering with the migration of polymorphs into the skin through inhibition of leukotriene B4 synthesis.
D000328:Adult; D000368:Aged; D001091:Arachidonate Lipoxygenases; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007975:Leukotriene B4 / Q000037:antagonists & inhibitors; D016859:Lipoxygenase Inhibitors; D008297:Male; D008875:Middle Aged; D011422:Propionates / Q000627:therapeutic use*; D011565:Psoriasis / Q000188:drug therapy* / Q000209:etiology
D016859:Lipoxygenase Inhibitors; D011422:Propionates; C011677:benoxaprofen; D007975:Leukotriene B4; D001091:Arachidonate Lipoxygenases